Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengzhan Xixin Injection for Acute Ischemic Stroke
ChiCTR-IPR-17011051Phase 4Recruiting
- Sponsor
- Centre for Beijing Aging Brain Rejuvenation initiative.Beijing Normal University
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Dengzhanxixin in ischemic stroke and post-stroke cognitive impairment (PSCI) (2 arms), sponsored by Centre for Beijing Aging Brain Rejuvenation initiative.Beijing Normal University. Primary endpoints: NIH Stroke Scale (NIHSS), Verbal Fluency Test and 7 more. Started Apr 2017; status: recruiting.
02
Drugs
Dengzhanxixin
03
Conditions
ischemic strokepost-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on ChiCTR-IPR-17011051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011051.